Our faculty research in diverse subjects: psychosomatic issues, pain management, patient reporting and compliance behaviors, whole community and family roles in psychiatric conditions and treatment, teaching strategies and much more.
Steven Dubovsky, MD
A Phase 3, Randomized, double-blind, placebo-controlled, parallel-group, multicenter, fixed-dose clinical trial evaluating the efficacy, safety and tolerability of cariprazine in patients with bipolar I depression. Steven Dubovsky (Principal Investigator). Allergan. $200,000. 1/1/2017-1/1/2019.
Study to evaluate the efficacy and safety of intranasal esketamine in addition to comprehensive standard of care for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in adult subjects. Steven Dubovsky (Principal Investigator). $188,000. 1/1/2017-1/1/2021.
Study to evaluate the efficacy and safety of intranasal esketamine in addition to comprehensive standard of care for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in pediatric subjects. Steven Dubovsky (Co-Investigator). Janssen Research & Development. 1/1/2017-1/1/2022.
Pain medication prescription following treatment for alcohol use disorder. Kenneth Leonard (Co-Principal Investigator), Edward Bednarczyk (Co-Investigator), Peter Elkin (Co-Principal Investigator), Walter Gibson (Co-Investigator), David Jacobs (Co-Investigator). National Institute on Alcoholism and Alcohol Abuse. $386,013. 7/1/2018-6/1/2020.
Expansion of MAT Practice in New York State. Kenneth Leonard (Principal Investigator), Brian Quigley (Co-Investigator). NYS OASAS. $750,000. 6/1/2017-5/1/2019.
In this custom-designed psychophysiology lab, our faculty, residents and fellows study the mechanisms by which the mind affects the body in psychosomatic illness by measuring heart rate and heart rate variability under lab stress conditions.